| A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors (NCT03000257) | AbbVie | 2016-12-14 |
| First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors (NCT02729298) | Sumitomo Pharma America, Inc. | 2016-12-14 |
| A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) (NCT02974738) | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2016-12-07 |
| Study of Samalizumab in Patients With Advanced Cancer (NCT02987504) | Alexion Pharmaceuticals, Inc. | 2016-11-17 |
| A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors (NCT03077607) | Pfizer | 2016-11-07 |
| A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors (NCT02829723) | Novartis Pharmaceuticals | 2016-10-21 |
| A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (NCT02936102) | Novartis Pharmaceuticals | 2016-10-20 |
| A Study of SC10914 in Patients With Advanced Solid Tumors (NCT02940132) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2016-10-01 |
| An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) (NCT02997176) | Pfizer | 2016-09-30 |
| A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors (NCT02799095) | Mural Oncology, Inc | 2016-09-14 |
| A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors (NCT02880371) | Pfizer | 2016-09-01 |
| A Study of Talazoparib in Patients With Advanced Solid Tumors (NCT03070548) | Pfizer | 2016-09-01 |
| A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study (NCT02875548) | Epizyme, Inc. | 2016-08-30 |
| Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors (NCT02900157) | MedImmune LLC | 2016-08-09 |
| Study of Apatinib and MASCT in Patients With Advanced Solid Tumors (NCT02844881) | The First People's Hospital of Lianyungang | 2016-07-01 |
| Study of Pexidartinib in Asian Subjects With Advanced Solid Tumors (NCT02734433) | Daiichi Sankyo Co., Ltd. | 2016-06-01 |
| Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors (NCT02611024) | PharmaMar | 2016-05-06 |
| A Study of Irinotecan Hydrochloride Liposome in Combination With 5-FU/LV in Advanced Solid Tumors (NCT05086848) | Jiangsu HengRui Medicine Co., Ltd. | 2016-05-05 |
| Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial (NCT02561455) | Astellas Pharma Global Development, Inc. | 2016-05-03 |
| A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects (NCT02721589) | Jiangsu HengRui Medicine Co., Ltd. | 2016-04-06 |
| Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors (NCT02644369) | University Health Network, Toronto | 2016-03-21 |
| Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors (NCT02456883) | Astellas Pharma Global Development, Inc. | 2016-03-04 |
| An Open Study Assessing the Safety and Tolerability of U3-1784 (NCT02690350) | Daiichi Sankyo | 2016-02-29 |
| A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors (NCT02671435) | MedImmune LLC | 2016-02-22 |
| Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer (NCT02546531) | Washington University School of Medicine | 2016-02-03 |
| A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors (NCT02743637) | SynDevRx, Inc. | 2016-02-01 |
| ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors (NCT02551185) | Celgene | 2015-12-22 |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) (NCT02628067) | Merck Sharp & Dohme LLC | 2015-12-18 |
| Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors (NCT02614456) | Fox Chase Cancer Center | 2015-12-11 |
| Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients (NCT02622932) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2015-12-02 |
| A Study in Adult Subjects With Select Advanced Solid Tumors (NCT02583165) | MedImmune LLC | 2015-11-09 |
| A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma (NCT02609230) | Fox Chase Cancer Center | 2015-11-05 |
| ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors (NCT02565758) | AbbVie | 2015-09-18 |
| Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy (NCT02516813) | EMD Serono Research & Development Institute, Inc. | 2015-09-15 |
| Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers (NCT02526017) | Five Prime Therapeutics, Inc. | 2015-09-08 |
| Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors (NCT02454972) | PharmaMar | 2015-08-25 |
| A Study Of PF-03084014 In Japanese Patients With Advanced Solid Tumors (NCT02462707) | Pfizer | 2015-07-01 |
| Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (NCT02460224) | Novartis Pharmaceuticals | 2015-06-17 |
| Safety Study of AMG 228 to Treat Solid Tumors (NCT02437916) | Amgen | 2015-04-21 |
| A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors (NCT02442414) | Sihuan Pharmaceutical Holdings Group Ltd. | 2015-04-07 |
| A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors (NCT02432326) | Sumitomo Pharma America, Inc. | 2015-04-01 |
| Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors (NCT02367352) | Millennium Pharmaceuticals, Inc. | 2015-03-19 |
| A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors (NCT02318394) | MedImmune LLC | 2015-03-02 |
| A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma (NCT02354898) | Sumitomo Pharma Co., Ltd. | 2015-03-01 |
| A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment (NCT02301117) | Taiho Oncology, Inc. | 2015-01-01 |
| A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment (NCT02301104) | Taiho Oncology, Inc. | 2015-01-01 |
| Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia (NCT02316197) | Merck KGaA, Darmstadt, Germany | 2014-12-31 |
| A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma (NCT02110355) | Kartos Therapeutics, Inc. | 2014-12-19 |
| Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors (NCT02301130) | Kyowa Kirin, Inc. | 2014-11-26 |
| Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors (NCT02318329) | Five Prime Therapeutics, Inc. | 2014-11-01 |
| A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma (NCT02259010) | Millennium Pharmaceuticals, Inc. | 2014-10-22 |
| A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors (NCT02261220) | MedImmune LLC | 2014-10-13 |
| A Phase 1 Study Evaluating CB-5083 in Subjects With Advanced Solid Tumors (NCT02243917) | Cleave Biosciences, Inc. | 2014-10-11 |
| ONO-4538 Phase I Study in Patients With Solid Tumor (NCT02261298) | Ono Pharmaceutical Co., Ltd. | 2014-10-01 |
| ONO-4538 Phase I Study in Patients With Solid Tumor (NCT02261285) | Ono Pharmaceutical Co., Ltd. | 2014-10-01 |
| Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors (NCT02281409) | Memorial Sloan Kettering Cancer Center | 2014-10-01 |
| An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma (NCT02253992) | Bristol-Myers Squibb | 2014-09-29 |
| Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors (NCT02197572) | Calithera Biosciences, Inc | 2014-09-15 |
| A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors (NCT05086822) | Jiangsu HengRui Medicine Co., Ltd. | 2014-09-09 |
| An Investigation of TAS-119 Monotherapy (NCT02448589) | Taiho Oncology, Inc. | 2014-09-01 |
| Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function (NCT02214147) | Millennium Pharmaceuticals, Inc. | 2014-08-21 |
| A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies (NCT02205333) | MedImmune LLC | 2014-08-13 |
| A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036) (NCT02179918) | Pfizer | 2014-08-01 |
| Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors (NCT02134067) | Taiho Oncology, Inc. | 2014-08-01 |
| Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors (NCT01980667) | PharmaMar | 2014-07-30 |
| A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors (NCT02210663) | AbbVie | 2014-07-01 |
| A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts (NCT02266745) | Promontory Therapeutics Inc. | 2014-07-01 |
| A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors (NCT01946789) | Altor BioScience | 2014-05-01 |
| A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial (NCT02057380) | Astellas Pharma Global Development, Inc. | 2014-04-16 |
| Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors (NCT02122770) | Millennium Pharmaceuticals, Inc. | 2014-04-01 |
| Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB (NCT01953783) | Millennium Pharmaceuticals, Inc. | 2014-03-19 |
| Study of the AL3810 in the Treatment of Advanced Solid Tumor (NCT03117101) | Haihe Biopharma Co., Ltd. | 2014-03-01 |
| A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors (NCT01999972) | Pfizer | 2014-02-26 |
| First-In-Human Phase I Trial of Ningetinib ( CT053PTSA ) in the Patients With Advanced Solid Tumors (NCT04577703) | Sunshine Lake Pharma Co., Ltd. | 2014-02-08 |
| Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations (NCT01989546) | National Cancer Institute (NCI) | 2014-02-04 |
| Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors (NCT02031055) | Taiho Oncology, Inc. | 2014-02-01 |
| A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of PQR309 (NCT01940133) | PIQUR Therapeutics AG | 2014-01-01 |
| Phase 1b Trial of BGJ398/BYL719 in Solid Tumors (NCT01928459) | Novartis Pharmaceuticals | 2013-10-01 |
| A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours (NCT01938612) | AstraZeneca | 2013-09-12 |
| A Study of ABT-165 in Subjects With Solid Tumors (NCT01946074) | AbbVie | 2013-08-08 |
| Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction (NCT01912222) | Millennium Pharmaceuticals, Inc. | 2013-08-01 |
| Phase I, Dose-Escalation Study of Soluble Beta-Glucan (SBG) in Patients With Advanced Solid Tumors (NCT01910597) | Prince of Songkla University | 2013-08-01 |
| Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas (NCT01898078) | Millennium Pharmaceuticals, Inc. | 2013-07-16 |
| Trial to Study the Safety of Intravenous MNK-010 in Advanced Solid Tumors (NCT02040558) | Mallinckrodt | 2013-07-01 |
| A Phase I Study of LEE011 in Asian Patients (NCT01898845) | Novartis Pharmaceuticals | 2013-05-01 |
| Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone (NCT01867866) | Taiho Oncology, Inc. | 2013-05-01 |
| A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid Tumors (NCT01847118) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2013-04-01 |
| A Trial of TAS-114 in Combination With S-1 (NCT02454062) | Taiho Oncology, Inc. | 2013-03-01 |
| Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies (NCT01781429) | BioMed Valley Discoveries, Inc | 2013-03-01 |
| Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib (NCT01714947) | Millennium Pharmaceuticals, Inc. | 2013-01-24 |
| A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma (NCT01723020) | Kartos Therapeutics, Inc. | 2012-12-27 |
| Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors (NCT01706835) | ImmunityBio, Inc. | 2012-10-01 |
| A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy (NCT01668017) | Merck KGaA, Darmstadt, Germany | 2012-09-30 |
| A Phase 1/2 Study to Evaluate MEDI4736 (NCT01693562) | MedImmune LLC | 2012-09-05 |
| Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors (NCT01576666) | Novartis Pharmaceuticals | 2012-07-01 |
| A Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors (NCT01610479) | Taiho Pharmaceutical Co., Ltd. | 2012-06-01 |
| First in Human Trial of TAS266 in Patients With Advanced Solid Tumors (NCT01529307) | Novartis Pharmaceuticals | 2012-06-01 |
| Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer (NCT01625234) | Xcovery Holdings, Inc. | 2012-06-01 |
| BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer (NCT01571024) | UNC Lineberger Comprehensive Cancer Center | 2012-05-01 |
| A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body (NCT01529684) | Astellas Pharma Global Development, Inc. | 2012-03-19 |